

Cephapirin / Prednisolone Formulation

| | | | |
|---------|----------------|--------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 28.09.2024 |
| 5.1 | 14.04.2025 | 764060-00020 | Date of first issue: 16.06.2016 |

Section 1: Identification

Product name : Cephapirin / Prednisolone Formulation

Other means of identification : Mastiplan (A011329)

Manufacturer or supplier's details

Company : MSD

Address : 33 Whakatiki Street - Private Bag 908
Upper Hutt - New Zealand

Telephone : 0800 800 543

Emergency telephone number : 0800 764 766 (0800 POISON) 0800 243 622 (0800
CHEMCALL)

E-mail address : EHSDATASTEWARD@msd.com

Recommended use of the chemical and restrictions on use

Recommended use : Veterinary product

Restrictions on use : Not applicable

Section 2: Hazard identification**GHS Classification**

Respiratory sensitisation : Category 1

Reproductive toxicity : Category 2

GHS label elements

Hazard pictograms :



Signal word : Danger

Hazard statements : H334 May cause allergy or asthma symptoms or breathing
difficulties if inhaled.
H361d Suspected of damaging the unborn child.

Precautionary statements : **Prevention:**
P201 Obtain special instructions before use.
P202 Do not handle until all safety precautions have been read
and understood.

Cephapirin / Prednisolone Formulation

| | | | |
|---------|----------------|--------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 28.09.2024 |
| 5.1 | 14.04.2025 | 764060-00020 | Date of first issue: 16.06.2016 |

P261 Avoid breathing mist or vapours.
P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.
P284 Wear respiratory protection.

Response:

P304 + P340 IF INHALED: Remove person to fresh air and keep comfortable for breathing.
P308 + P313 IF exposed or concerned: Get medical advice/ attention.
P342 + P311 If experiencing respiratory symptoms: Call a POISON CENTER/ doctor.

Storage:

P405 Store locked up.

Disposal:

P501 Dispose of contents/ container to an approved waste disposal plant.

Other hazards which do not result in classification

None known.

Section 3: Composition/information on ingredients

Substance / Mixture : Mixture

Components

| Chemical name | CAS-No. | Concentration (% w/w) |
|-----------------------|------------|-----------------------|
| Glyceryl monostearate | 123-94-4 | >= 1 -< 10 |
| Cefapirin | 21593-23-7 | >= 1 -< 10 |
| prednisolone | 50-24-8 | >= 0.25 -< 1 |

Section 4: First-aid measures

| | |
|-------------------------|---|
| General advice | : In the case of accident or if you feel unwell, seek medical advice immediately. When symptoms persist or in all cases of doubt seek medical advice. |
| If inhaled | : If inhaled, remove to fresh air. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical attention. |
| In case of skin contact | : In case of contact, immediately flush skin with soap and plenty of water. Remove contaminated clothing and shoes. Get medical attention. Wash clothing before reuse. Thoroughly clean shoes before reuse. |
| In case of eye contact | : Flush eyes with water as a precaution. Get medical attention if irritation develops and persists. |
| If swallowed | : If swallowed, DO NOT induce vomiting. |

Cephapirin / Prednisolone Formulation

| | | | |
|---------|----------------|--------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 28.09.2024 |
| 5.1 | 14.04.2025 | 764060-00020 | Date of first issue: 16.06.2016 |

| | |
|---|--|
| Most important symptoms and effects, both acute and delayed | : Get medical attention. Rinse mouth thoroughly with water. Excessive exposure may aggravate preexisting asthma and other respiratory disorders (e.g. emphysema, bronchitis, reactive airways dysfunction syndrome). May cause allergy or asthma symptoms or breathing difficulties if inhaled. |
| Protection of first-aiders | : Suspected of damaging the unborn child. First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8). |
| Notes to physician | : Treat symptomatically and supportively. |

Section 5: Fire-fighting measures

| | |
|---|---|
| Suitable extinguishing media | : Water spray Alcohol-resistant foam Carbon dioxide (CO ₂) Dry chemical |
| Unsuitable extinguishing media | : None known. |
| Specific hazards during fire-fighting | : Exposure to combustion products may be a hazard to health. |
| Hazardous combustion products | : Carbon oxides Metal oxides Silicon oxides |
| Specific extinguishing methods | : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area. |
| Special protective equipment for firefighters | : In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment. |

Section 6: Accidental release measures

| | |
|---|---|
| Personal precautions, protective equipment and emergency procedures | : Use personal protective equipment. Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8). |
| Environmental precautions | : Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Prevent spreading over a wide area (e.g. by containment or oil barriers). Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages |

Cephapirin / Prednisolone Formulation

| | | | |
|---------|----------------|--------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 28.09.2024 |
| 5.1 | 14.04.2025 | 764060-00020 | Date of first issue: 16.06.2016 |

cannot be contained.

Methods and materials for containment and cleaning up : Soak up with inert absorbent material.
For large spills, provide dyking or other appropriate containment to keep material from spreading. If dyked material can be pumped, store recovered material in appropriate container. Clean up remaining materials from spill with suitable absorbent.
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

Section 7: Handling and storage

| | | |
|-----------------------------|---|--|
| Technical measures | : | See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section. |
| Local/Total ventilation | : | Use only with adequate ventilation. |
| Advice on safe handling | : | Do not breathe mist or vapours. Do not swallow. Avoid contact with eyes. Avoid prolonged or repeated contact with skin. Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment Keep container tightly closed. Already sensitised individuals, and those susceptible to asthma, allergies, chronic or recurrent respiratory disease, should consult their physician regarding working with respiratory irritants or sensitisers. Take care to prevent spills, waste and minimize release to the environment. |
| Hygiene measures | : | If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use. The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls. |
| Conditions for safe storage | : | Keep in properly labelled containers. Keep tightly closed. Store in accordance with the particular national regulations. |
| Materials to avoid | : | Do not store with the following product types: Strong oxidizing agents |

Cephapirin / Prednisolone Formulation

Version 5.1 Revision Date: 14.04.2025 SDS Number: 764060-00020 Date of last issue: 28.09.2024
Date of first issue: 16.06.2016

Section 8: Exposure controls/personal protection

Components with workplace control parameters

| Components | CAS-No. | Value type (Form of exposure) | Control parameters / Permissible concentration | Basis |
|---------------------------|------------|-------------------------------------|--|----------|
| Glyceryl monostearate | 123-94-4 | WES-TWA | 10 mg/m ³ | NZ OEL |
| | | TWA (Inhalable particulate matter) | 10 mg/m ³ | ACGIH |
| | | TWA (Respirable particulate matter) | 3 mg/m ³ | ACGIH |
| Cefapirin | 21593-23-7 | TWA | 0.4 mg/m ³ (OEB 2) | Internal |
| Further information: RSEN | | | | |
| prednisolone | 50-24-8 | TWA | 10 µg/m ³ (OEB 3) | Internal |
| | | Wipe limit | 100 µg/100 cm ² | Internal |

Engineering measures : Use appropriate engineering controls and manufacturing technologies to control airborne concentrations (e.g., drip-less quick connections).
All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.
Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices).
Minimize open handling.

Personal protective equipment

Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

Filter type : Combined particulates and organic vapour type

Hand protection

Material : Chemical-resistant gloves

Remarks : Consider double gloving.

Eye protection : Wear safety glasses with side shields or goggles.
If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.
Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Skin and body protection : Work uniform or laboratory coat.
Additional body garments should be used based upon the

Cephapirin / Prednisolone Formulation

| | | | |
|---------|----------------|--------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 28.09.2024 |
| 5.1 | 14.04.2025 | 764060-00020 | Date of first issue: 16.06.2016 |

task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces.
Use appropriate degowning techniques to remove potentially contaminated clothing.

Section 9: Physical and chemical properties

| | | |
|--|---|-------------------|
| Appearance | : | liquid, oily |
| Colour | : | No data available |
| Odour | : | No data available |
| Odour Threshold | : | No data available |
| pH | : | No data available |
| Melting point/freezing point | : | No data available |
| Initial boiling point and boiling range | : | No data available |
| Flash point | : | No data available |
| Evaporation rate | : | No data available |
| Flammability (solid, gas) | : | Not applicable |
| Flammability (liquids) | : | No data available |
| Upper explosion limit / Upper flammability limit | : | No data available |
| Lower explosion limit / Lower flammability limit | : | No data available |
| Vapour pressure | : | No data available |
| Relative vapour density | : | No data available |
| Density | : | No data available |
| Solubility(ies) | | |
| Water solubility | : | No data available |
| Partition coefficient: n-octanol/water | : | No data available |
| Auto-ignition temperature | : | No data available |
| Decomposition temperature | : | No data available |
| Viscosity | | |
| Viscosity, kinematic | : | No data available |

Cephapirin / Prednisolone Formulation

| | | | |
|---------|----------------|--------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 28.09.2024 |
| 5.1 | 14.04.2025 | 764060-00020 | Date of first issue: 16.06.2016 |

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Molecular weight : No data available

Particle characteristics
Particle size : No data available

Section 10: Stability and reactivity

Reactivity : Not classified as a reactivity hazard.

Chemical stability : Stable under normal conditions.

Possibility of hazardous reactions : Can react with strong oxidizing agents.

Conditions to avoid : None known.

Incompatible materials : Oxidizing agents

Hazardous decomposition products : No hazardous decomposition products are known.

Section 11: Toxicological information

Exposure routes : Inhalation
Skin contact
Ingestion
Eye contact

Acute toxicity

Not classified based on available information.

Components:**Glyceryl monostearate:**

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg
Method: OECD Test Guideline 401
Remarks: Based on data from similar materials

Acute dermal toxicity : LD50 (Rat): > 2,000 mg/kg
Remarks: Based on data from similar materials

Cefapirin:

Acute oral toxicity : LD50 (Mouse): 26,000 mg/kg

Acute toxicity (other routes of administration) : LD50 (Mouse): > 7,600 mg/kg
Application Route: Intraperitoneal

LD50 (Rat): 7,800 mg/kg
Application Route: Intraperitoneal

Cephapirin / Prednisolone Formulation

| | | | |
|---------|----------------|--------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 28.09.2024 |
| 5.1 | 14.04.2025 | 764060-00020 | Date of first issue: 16.06.2016 |

prednisolone:

Acute oral toxicity : LD50 (Mouse): 1,680 mg/kg
LD50 (Rat): > 3,857 mg/kg

Acute inhalation toxicity : Remarks: No data available

Acute dermal toxicity : Remarks: No data available

Acute toxicity (other routes of administration) : LD50 (Rat): 147 mg/kg
Application Route: Subcutaneous
LD50 (Mouse): 767 mg/kg
Application Route: Intraperitoneal

Skin corrosion/irritation

Not classified based on available information.

Components:**Glyceryl monostearate:**

Species : Rabbit
Result : No skin irritation
Remarks : Based on data from similar materials

prednisolone:

Remarks : No data available

Serious eye damage/eye irritation

Not classified based on available information.

Components:**Glyceryl monostearate:**

Species : Rabbit
Result : No eye irritation
Remarks : Based on data from similar materials

prednisolone:

Remarks : No data available

Respiratory or skin sensitisation**Skin sensitisation**

Not classified based on available information.

Respiratory sensitisation

May cause allergy or asthma symptoms or breathing difficulties if inhaled.

Cephapirin / Prednisolone Formulation

| | | | |
|---------|----------------|--------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 28.09.2024 |
| 5.1 | 14.04.2025 | 764060-00020 | Date of first issue: 16.06.2016 |

Components:**Glyceryl monostearate:**

| | | |
|-----------------|---|--------------------------------------|
| Test Type | : | Buehler Test |
| Exposure routes | : | Skin contact |
| Species | : | Guinea pig |
| Result | : | negative |
| Remarks | : | Based on data from similar materials |

Cefapirin:

| | | |
|------------|---|--|
| Assessment | : | Probability or evidence of high respiratory sensitisation rate in humans |
|------------|---|--|

prednisolone:

| | | |
|---------|---|-------------------|
| Remarks | : | No data available |
|---------|---|-------------------|

Chronic toxicity**Germ cell mutagenicity**

Not classified based on available information.

Components:**Glyceryl monostearate:**

| | | |
|-----------------------|---|--|
| Genotoxicity in vitro | : | Test Type: Chromosome aberration test in vitro Method: OECD Test Guideline 473 Result: negative Remarks: Based on data from similar materials |
| | | Test Type: Bacterial reverse mutation assay (AMES) Method: OECD Test Guideline 471 Result: negative Remarks: Based on data from similar materials |
| | | Test Type: In vitro mammalian cell gene mutation test Result: negative Remarks: Based on data from similar materials |

Cefapirin:

| | | |
|-----------------------|---|--|
| Genotoxicity in vitro | : | Test Type: Bacterial reverse mutation assay (AMES) Result: negative |
|-----------------------|---|--|

prednisolone:

| | | |
|-----------------------|---|--|
| Genotoxicity in vitro | : | Test Type: Bacterial reverse mutation assay (AMES) Result: negative |
| | | Test Type: Mouse Lymphoma Result: negative |

Cephapirin / Prednisolone Formulation

| | | | |
|---------|----------------|--------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 28.09.2024 |
| 5.1 | 14.04.2025 | 764060-00020 | Date of first issue: 16.06.2016 |

| | |
|----------------------|---|
| | Test Type: sister chromatid exchange assay Result: negative |
| Genotoxicity in vivo | : Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay) Species: Rat Application Route: Oral Result: negative |
| | Test Type: sister chromatid exchange assay Species: Humans Result: negative |

Carcinogenicity

Not classified based on available information.

Components:**prednisolone:**

| | |
|-------------------|-------------|
| Species | : Rat |
| Application Route | : Oral |
| Exposure time | : 18 Months |
| Result | : negative |

Reproductive toxicity

Suspected of damaging the unborn child.

Components:**Glyceryl monostearate:**

| | |
|----------------------|--|
| Effects on fertility | : Test Type: Combined repeated dose toxicity study with the reproduction/developmental toxicity screening test Species: Rat Application Route: Ingestion Method: OECD Test Guideline 422 Result: negative Remarks: Based on data from similar materials |
|----------------------|--|

| | |
|-------------------------------|--|
| Effects on foetal development | : Test Type: Combined repeated dose toxicity study with the reproduction/developmental toxicity screening test Species: Rat Application Route: Ingestion Method: OECD Test Guideline 422 Result: negative Remarks: Based on data from similar materials |
|-------------------------------|--|

Cefapirin:

| | |
|----------------------|---|
| Effects on fertility | : Test Type: Fertility/early embryonic development Species: Rat Application Route: Intraperitoneal injection Fertility: LOAEL: > 500 mg/kg body weight |
|----------------------|---|

Cephapirin / Prednisolone Formulation

| | | | |
|---------|----------------|--------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 28.09.2024 |
| 5.1 | 14.04.2025 | 764060-00020 | Date of first issue: 16.06.2016 |

Result: No effects on fertility

Effects on foetal development : Test Type: Embryo-foetal development
Species: Rat
Application Route: Intraperitoneal injection
Developmental Toxicity: LOAEL: > 200 mg/kg body weight

prednisolone:

Effects on fertility : Test Type: Fertility/early embryonic development
Species: Rat
Application Route: Subcutaneous
Fertility: NOAEL: 1 mg/kg body weight
Result: No effects on fertility

Effects on foetal development : Test Type: Embryo-foetal development
Species: Mouse
Application Route: Oral
Developmental Toxicity: LOAEL: 0.5 mg/kg body weight
Result: Malformations were observed., Cleft palate

Test Type: Embryo-foetal development
Species: Rat
Application Route: Oral
Developmental Toxicity: LOAEL: 30 mg/kg body weight
Result: decreased blood formation

Species: Rat
Application Route: Subcutaneous
Developmental Toxicity: NOAEL: 25 mg/kg body weight
Result: No effects on foetal development

Reproductive toxicity - Assessment : Some evidence of adverse effects on development, based on animal experiments.

STOT - single exposure

Not classified based on available information.

STOT - repeated exposure

Not classified based on available information.

Components:**prednisolone:**

Target Organs : Bone marrow, Adrenal gland, Liver
Assessment : Causes damage to organs through prolonged or repeated exposure.

Cephapirin / Prednisolone Formulation

| | | | |
|---------|----------------|--------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 28.09.2024 |
| 5.1 | 14.04.2025 | 764060-00020 | Date of first issue: 16.06.2016 |

Repeated dose toxicity**Components:****Glyceryl monostearate:**

| | |
|-------------------|--|
| Species | : Rat |
| NOAEL | : $\geq 12,500$ mg/kg |
| Application Route | : Ingestion |
| Exposure time | : 84 Days |
| Remarks | : Based on data from similar materials |

Cefapirin:

| | |
|-------------------|--------------------|
| Species | : Rat |
| LOAEL | : ≥ 200 mg/kg |
| Application Route | : Intraperitoneal |
| Target Organs | : Blood |
| Remarks | : anemia |

| | |
|-------------------|--------------------------|
| Species | : Dog |
| LOAEL | : 20 mg/kg |
| Application Route | : Oral |
| Exposure time | : 4 Months |
| Target Organs | : Gastrointestinal tract |

| | |
|-------------------|---------------------------------|
| Species | : Dog |
| LOAEL | : 100 mg/kg |
| Application Route | : Intramuscular |
| Exposure time | : 10 Months |
| Target Organs | : Blood, Gastrointestinal tract |
| Remarks | : anemia |

prednisolone:

| | |
|-------------------|---------------|
| Species | : Rat |
| LOAEL | : 0.6 mg/kg |
| Application Route | : Oral |
| Exposure time | : 63 Days |
| Target Organs | : Bone marrow |

| | |
|-------------------|-----------------|
| Species | : Dog |
| LOAEL | : 2.5 mg/kg |
| Application Route | : Oral |
| Exposure time | : 6 Weeks |
| Target Organs | : Adrenal gland |

| | |
|-------------------|------------|
| Species | : Rabbit |
| LOAEL | : 1 mg/kg |
| Application Route | : Oral |
| Exposure time | : 24 Weeks |
| Target Organs | : Liver |

Cephapirin / Prednisolone Formulation

| | | | |
|---------|----------------|--------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 28.09.2024 |
| 5.1 | 14.04.2025 | 764060-00020 | Date of first issue: 16.06.2016 |

Aspiration toxicity

Not classified based on available information.

Experience with human exposure**Components:****Cefapirin:**

Ingestion : Symptoms: Nausea, Vomiting, Abdominal pain, Diarrhoea, vaginitis, colitis, anorexia, Rash, anaphylaxis

prednisolone:

Ingestion : Symptoms: sodium retention, Headache, Vertigo, fluid retention, subcutaneous bleeding, striae, skin atrophy, menstrual irregularities

Section 12: Ecological information**Ecotoxicity****Components:****Glyceryl monostearate:**

Toxicity to fish : LL50 (Leuciscus idus (Golden orfe)): > 100 mg/l
Exposure time: 48 h
Remarks: Based on data from similar materials

Toxicity to daphnia and other aquatic invertebrates : EL50 (Daphnia magna (Water flea)): > 32 mg/l
Exposure time: 47 h
Method: Directive 67/548/EEC, Annex V, C.2.
Remarks: No toxicity at the limit of solubility
Based on data from similar materials

Toxicity to algae/aquatic plants : EL50 (Pseudokirchneriella subcapitata (green algae)): > 100 mg/l
Exposure time: 72 h
Test substance: Water Accommodated Fraction
Method: OECD Test Guideline 201
Remarks: No toxicity at the limit of solubility

NOELR (Pseudokirchneriella subcapitata (green algae)): > 1 mg/l
Exposure time: 72 h
Test substance: Water Accommodated Fraction
Method: OECD Test Guideline 201
Remarks: No toxicity at the limit of solubility

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC (Daphnia magna (Water flea)): > 0.22 mg/l
Exposure time: 21 d
Method: OECD Test Guideline 211
Remarks: No toxicity at the limit of solubility
Based on data from similar materials

Cephapirin / Prednisolone Formulation

| | | | |
|---------|----------------|--------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 28.09.2024 |
| 5.1 | 14.04.2025 | 764060-00020 | Date of first issue: 16.06.2016 |

Toxicity to microorganisms : EC10 (*Pseudomonas putida*): > 1 mg/l
Exposure time: 18 h
Remarks: Based on data from similar materials

prednisolone:

Toxicity to daphnia and other aquatic invertebrates : EC50 (*Daphnia magna* (Water flea)): > 85 mg/l
Exposure time: 48 h

Toxicity to algae/aquatic plants : NOEC (*Pseudokirchneriella subcapitata* (green algae)): 160 mg/l
Exposure time: 72 h

EC50 (*Pseudokirchneriella subcapitata* (green algae)): > 160 mg/l
Exposure time: 72 h

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC (*Ceriodaphnia dubia* (water flea)): 0.23 mg/l
Exposure time: 7 d

Persistence and degradability**Components:****Glyceryl monostearate:**

Biodegradability : Result: Readily biodegradable.
Remarks: Based on data from similar materials

Bioaccumulative potential**Components:****Glyceryl monostearate:**

Partition coefficient: n-octanol/water : log Pow: 6.1

prednisolone:

Partition coefficient: n-octanol/water : log Pow: 1.46

Mobility in soil

No data available

Other adverse effects

No data available

Section 13: Disposal considerations**Disposal methods**

Waste from residues : Do not dispose of waste into sewer.
Dispose of in accordance with local regulations.
Contaminated packaging : Empty containers should be taken to an approved waste han-

Cephapirin / Prednisolone Formulation

| | | | |
|---------|----------------|--------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 28.09.2024 |
| 5.1 | 14.04.2025 | 764060-00020 | Date of first issue: 16.06.2016 |

ding site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.

Section 14: Transport information**International Regulations****UNRTDG**

| | | |
|---------------------------|---|----------------|
| UN number | : | Not applicable |
| Proper shipping name | : | Not applicable |
| Class | : | Not applicable |
| Subsidiary risk | : | Not applicable |
| Packing group | : | Not applicable |
| Labels | : | Not applicable |
| Environmentally hazardous | : | no |

IATA-DGR

| | | |
|--|---|----------------|
| UN/ID No. | : | Not applicable |
| Proper shipping name | : | Not applicable |
| Class | : | Not applicable |
| Subsidiary risk | : | Not applicable |
| Packing group | : | Not applicable |
| Labels | : | Not applicable |
| Packing instruction (cargo aircraft) | : | Not applicable |
| Packing instruction (passenger aircraft) | : | Not applicable |

IMDG-Code

| | | |
|----------------------|---|----------------|
| UN number | : | Not applicable |
| Proper shipping name | : | Not applicable |
| Class | : | Not applicable |
| Subsidiary risk | : | Not applicable |
| Packing group | : | Not applicable |
| Labels | : | Not applicable |
| EmS Code | : | Not applicable |
| Marine pollutant | : | Not applicable |

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

National Regulations**NZS 5433**

| | | |
|----------------------|---|----------------|
| UN number | : | Not applicable |
| Proper shipping name | : | Not applicable |
| Class | : | Not applicable |
| Subsidiary risk | : | Not applicable |
| Packing group | : | Not applicable |
| Labels | : | Not applicable |
| Hazchem Code | : | Not applicable |

Special precautions for user

Not applicable

Cephapirin / Prednisolone Formulation

| | | | |
|---------|----------------|--------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 28.09.2024 |
| 5.1 | 14.04.2025 | 764060-00020 | Date of first issue: 16.06.2016 |

Section 15: Regulatory information**Safety, health and environmental regulations/legislation specific for the substance or mixture****HSNO Approval Number**

HSR100757 Veterinary Medicines Limited Pack Size Finished Dose Group Standard

Tolerable Exposure Limits (TEL)

Not applicable

Environmental Exposure Limits (EEL)

Not applicable

HSW Controls

Certified handler certificate not required.

Tracking hazardous substance not required.

Refer to the Health and Safety at Work (Hazardous Substances) Regulations 2017, for further information.

The components of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

Section 16: Other information

Revision Date : 14.04.2025

Further informationSources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Date format : dd.mm.yyyy

Full text of other abbreviations

ACGIH : USA. ACGIH Threshold Limit Values (TLV)

NZ OEL : New Zealand. Workplace Exposure Standards for Atmospheric Contaminants

ACGIH / TWA : 8-hour, time-weighted average

NZ OEL / WES-TWA : Workplace Exposure Standard - Time Weighted average

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with

Cephapirin / Prednisolone Formulation

| | | | |
|---------|----------------|--------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 28.09.2024 |
| 5.1 | 14.04.2025 | 764060-00020 | Date of first issue: 16.06.2016 |

x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

NZ / EN